Trial Profile

A Phase Ⅱ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mufemilast (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Sponsors Tianjin Hemay Pharmaceutical

Most Recent Events

11 Oct 2021 Status changed from active, no longer recruiting to completed.
25 Jun 2020 Planned End Date changed from 20 May 2021 to 12 Aug 2021.
25 Jun 2020 Planned primary completion date changed from 10 Apr 2020 to 8 Oct 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com